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Furazolidone is a nitrofuran derivative of nitrofurantoin that possesses antibacterial activity against both Gram-positive and Gram-negative bacteria. Due to the fact that some metabolites of furazolidone may have carcinogenic effects in animal models, its use has been forbidden in different countries, including the United States, (1) . Nonetheless, furazolidone has been extensively used in the treatment of different human infections. Thus, furazolidone is currently used for the treatment of parasitic infections by Giardia lamblia or Entamoeba histolytica (2, 3) or in the treatment of Helicobacter pylori infections (4) . Meanwhile, in South America it is considered an alternative treatment to the commonly prescribed antibiotics for children diarrhoea, because of the increasing levels of resistance to commonly used antibacterial agents (5) (6) (7) (8) , and due to its good activity against most Enterobacteriaceae and its low cost. Thus, the use of furazolidone is now being implemented for the treatment of these pathologies in different Latin American countries (9) (10) (11) .
Although the specific mode of action of nitrofurans is unclear, it has been shown that E. coli strains resistant and susceptible to nitrofurans differ in their ability to reduce these compounds (12) , suggesting that they need to be activated for this nitroreductase activity to show its antibiotic effect. Few data on the mechanisms involved in the development of nitrofuran resistance are available to date, demonstrating that the development of furazolidone resistance is mediated by the inactivation of the nitroreductases present in E. coli. Thus, Whiteway et al. (13) showed that the increased resistance of these bacteria is caused by successive mutations, insertions or deletions in the nitroreductase-encoding genes nfsA and nfsB, resulting in a sequential decrease in the nitrofuran reducing capacity.
Thus, the aim of this study was to determine the ability of furazolidone to select resistant mutants, analysing their stability and underlying mechanisms of resistance.
MATERIALS AND METHODS

Bacterial strains
Four clinical isolates of E. coli (2 enteroaggregative E. coli -EAEC; and 2 enterotoxigenic E. coli -ETEC) isolated from faeces collected from children under 2-year old with diarrhoea from periurban communities of Lima, Peru (5). These isolates were selected because are representative of the main diarrheogenic E. coli pathotypes. The exact isolates were chosen at random from the collections of the Universidad Peruana Cayetano Heredia.
Antimicrobial susceptibility test
The susceptibility to furazolidone and nitrofurantoin was established using the disk diffusion method in accordance with the CLSI guidelines (14) .
Minimal inhibitory concentration (MIC)
The MIC to furazolidone and nitrofurantoin and also to nalidixic acid, ampicillin, chloramphenicol and tetracycline was determined by the agar dilution method according to the CLSI (14) . The MICs were also determined by adding 20 mg/L of Phenyl-Arginine-ß-naphtylamide (PAßN) to evaluate the role of the PAßN inhibitable efflux pumps in the resistance to furazolidone. A control with this compound and with the antibiotic solvent (N-N-dimethylformamide) was also made to ensure that it did not interfere in the bacterial growth.
Development of furazolidone-resistant mutants
The isolates were grown in Luria-Bertani broth overnight and 100 lL was inoculated onto Mueller-Hinton plates containing serial dilutions of furazolidone from 1 9 MIC to 128 mg/L. The plates were incubated at 37°C and read at 24 and 48 h. To determine the original inoculum serial dilutions were performed. The experiments were performed in duplicate. The frequency of mutation was established as previously described (15) . The absence of contaminations was assessed by the study of clonal relations between parental and derived mutant strains by REP-PCR as described elsewhere (16) .
Determination of the stability of the furazolidoneresistant mutants selected
The stability of the selected mutants was established by making 20 consecutive passes without the antibiotic on MacConkey agar (17) . Thereafter, the MIC to furazolidone was repeated to observe possible differences between the first and the twentieth pass.
Nitroreductase gene amplification and sequencing
The presence of mutations in the nitroreductase genes nfsA and nfsB was determined by PCR as described previously (13) . The products were purified with Wizard SV Gel and the PCR Clean Up System (Promega, Madison, WI, USA) and sequenced (Macrogen, Seoul, Korea).
Nitroreductase activity assay
Protein extraction and the consequent enzymatic assay, performed in 96-well plates and in three independent assays, were made as described elsewhere (18) .
Study of the outer membrane proteins
Alterations in outer membrane proteins were studied by analysing differences between the patrons of the parental strains and mutants showed in electrophoresis in 12% acrylamide gel, at constant 40 mA and 150 V. Proteins were extracted as described by Tavio et al. (19) and visualized with a Coomassie staining. When differences were observed in the intensity of the bands in the gel, the products were recovered and sent to sequencing (University of Barcelona, Barcelona, Spain) for the identification of the protein.
RESULTS
Antimicrobial susceptibility
The MIC in the parental strains ranged from 0.25 to 2 mg/L. After mutant selection, 34 different colonies, 10 E. coli EAEC and 24 E. coli ETEC, were randomly selected and confirmed as mutants by REP-PCR. The mutants showed increases up to 3-fold in their MIC with respect to parental strain 1 (from 0.5 to 4 mg/L for furazolidone and 4 to 32 mg/L for nitrofurantoin), up to 2-fold with respect to parental strains 2 and 4 (ranging from 2 to 8 mg/L and 1 to 8 mg/L for furazolidone and 2 to 16 mg/L and 4 to 32 mg/L for nitrofurantoin respectively), and up to 5-fold with respect to parental strain 3 (from 0.25 to 8 mg/L). All MIC levels were proportional with zone diameters obtained in the disk diffusion test (Table 1) . Neither changes in the MIC levels with the addition of PAßN nor cross-resistance was observed with any of the antibiotics tested. Additionally, no differences in the MIC levels were obtained when the MIC was read at 24 or 48 h. The PAßN and the solvent had no inhibitory effect on the growth. No effect of N-N-dimethylformamide or PAßN in the bacterial growth was observed.
Stability and frequency of mutation of the furazolidone-resistant mutants selected
The frequency of mutation obtained ranged from <9.6 9 10 À10 to 9.59 9 10 À7 (Table 2) . After making 20 consecutive passes without antibiotic the MIC obtained in the mutants was not different from the initial.
Study of the nitroreductase genes
Seventeen mutant strains (50%) presented mutations in the nitroreductase A encoding gene (nfsA), producing the generation of a STOP codon in 15 (88.2%) of these isolates. Punctual amino acid changes in this gene were observed in the other two isolates. In the nitroreductase B gene (nfsB) a lower number of amino acid changes was generated in 3 isolates (8.8%), none with the generation of a STOP codon. One isolate (2.9%) presented amino acid changes in both nitroreductase genes, while 15 isolates (44%) remained without mutations. An overview of all these changes is specified in Table 1 .
Nitroreductase activity
Of the two isolates with mutations from parental strain 1, one showed no differences in nitroreductase activity and the other (with a STOP codon in the nfsA gene) showed a 20% decrease. The mutant from parental strain 2 and one mutant from parental strain 3 whose NfsB had an amino acid change, showed a decrease in nitroreductase activity of 25-40%. On the other hand, the mutant from parental strain 3 with a double mutation in the nfsA and nfsB genes showed a decrease of almost 50% in activity. Finally, in the mutants from parental strain 4, all with a codon STOP in NfsA nitroreductase, a decrease in the activity of 5-65% was observed. Results are shown in Fig. 1 and expressed in relation to parental strains.
Outer membrane proteins
Sequencing showed that the two porins with a different profile expression in a polyacrlylamide gel were OmpA and OmpW. The first showed both overexpression in one mutant and lower expression in 27 mutants (82.3%), while 14 mutants (41.2%) showed a decrease in the expression of OmpW, all compared with the parental strains ( Table 1, Fig. 2 ).
DISCUSSION
The standard treatment used in cases of diarrhoea is limited to only fluid replacement. However, due to the specific virulence of the pathogen, the disease duration or the general status of the patient, which may also be influenced by nutritional status, the use of antibiotics is sometimes necessary (20) . The most widely used group of antimicrobials in infections caused by Enterobacteriaceae are currently b-lactams or cotrimoxazole, however, resistance levels to these antibiotics have been increasing over the years (21) . Although safe (22) , quinolones, such as ciprofloxacin, which are extensively used in the treatment of adult diarrhoea, are sparingly used in the treatment of children diarrhoea. Moreover, since the 1990s, an increase in the levels of quinolone resistance has been described worldwide, affecting both commensal and pathogenic microorganisms (5, 6, 8) . At present, the World Health Organization considers the problem of antimicrobial resistance a priority (23) .
In this context, furazolidone is increasingly used in different low and middle income settings (9-11), as treatment for different diarrheic pathogens.
Present data showed that furazolidone generally presents low mutation frequencies, ranging from <9.6 9 10 À10 to 9.59 9 10 À7 , demonstrating the low potential of this antimicrobial agent for selecting resistant mutants. These frequencies of mutation were lower than those described for other antimicrobial agents such as rifaximin or rifampicin, and similar to that of azithromycin or ciprofloxacin (15, 17) . The MIC of furazolidone obtained in the mutants reached levels of between 2 and 8 mg/L, being considered as intermediate in 35 of 37 mutants in which the MIC levels were equal or higher than 4 mg/L. Present data are in accordance with the fact that more than one mutation step is needed to achieve high levels of furazolidone resistance (13) . Moreover, no differences in the MIC values were observed between the initial values and after 20 growth passes without antibiotic pressure, thus, the mutations acquired are time-stable. The additive effect of sequential target mutation has been previously described in the selection of resistance to other antimicrobial agents such as the quinolones (8). Due to this additive effect, the stability of selected mutants and the fact that intermediate MIC levels may be reached in a single step, and then a potential full-resistance may be selected in a subsequent mutation step; when used, the levels of furazolidone resistant need to be monitored in continuous manner.
In the presence of the efflux pump inhibitor PAßN, the expected decreases in the MIC values were not found, thus efflux pumps inhibited by PAßN do not play an important role in the acquisition of resistance to furazolidone, unlike other antibiotics previously described such as nalidixic acid, azithromycin or rifaximin (7, 15, 24) . The MIC was determined both in the presence and the absence of inhibitor, reading the results at 24 and 48 h and no differences were found, demonstrating that no inducible furazolidone-resistance mechanism was selected. Cross-resistance was not found showing that the use of furazolidone probably will not affect the levels of susceptibility to nalidixic acid, ampicillin, chloramphenicol and tetracycline.
The nfsA and nfsB genes were sequenced to analyse the mechanisms of resistance selected in our strains. Different to that observed previously (13) , in which all first-step mutants presents alterations in the nfsA gene, in this study were found mutations in the nfsA or nfsB genes, or in both genes concomitantly. Thus, mutations in nfsA and/or nfsB were found in the 55.8% (19 of 34) of the mutants. However, although the presence of these alterations explains the rise in the MIC levels, these levels remained remarkably low. When a STOP codon was selected at amino acid codon 76 of NfsA, a truncated nitroreductase was produced, thereby not allowing the antibiotic to metabolize and consequently, remaining in the bacteria for a longer time without affecting it. This is explained by the inactivation of nitroreductases which causes the acquisition of resistance to nitrofurans as shown in Fig. 1  (12, 13) . The generation of a terminal codon was not observed in the 3 isolates (8.8%) with alterations in the nitroreductase gene nfsB.
On assessing the activity of these enzymes, all the mutant strains that generated STOP codons in their nfsA gene and the double mutants showed an important decrease in their activity. It is important to also consider that some mutants without mutations in the nitroreductase genes had less activity, demonstrating the presence of other furazolidoneresistant mechanisms. Similar fact was observed in previous studies, in which both an increase in furazolidone-MIC levels and a decrease in the activity of nitroreductase activity were confirmed in absence of acquisition of target mutations (13) . In this case, the authors adduce as explanations the possible presence of other enzymes possessing nitroreductase activity, presence of essential transacting factor or alterations affecting furazolidone uptake.
The study of the outer membrane proteins showed differences in the expression of either over or under OmpA expression. This may be due, not only to an adaptation to the antibiotic but also to the mutations in the resistant strains caused by the presence of furazolidone that could lead to an internal alteration in the cellular machinery due to the production of oxidative stress (25) . However, in E. coli or Citrobacter freundii has been observed that the increase in the expression of OmpA may be associated with decreased susceptibility to tetracycline and carbapenems (26, 27) , Smani et al. (28) showed that the disruption of the ompA gene in Acinetobacter baumannii led to decreased MICs of chloramphenicol, aztreonam, and nalidixic acid. These authors propose that the loss of OmpA may disturb membrane processes, including the transport of antimicrobial agents. Moreover, the changes found in OmpW profile expression, which decreased in all mutant strains affected, could be the cause of the increment in MIC levels. Other studies have previously demonstrated that the OmpW porin could be overexpressed when resistance to some antimicrobial agents is selected (29) , suggesting that this porin acts by expulsing the antibiotic outside the cell leading to a higher antimicrobial tolerance (30) . Nevertheless, in accordance with our results, other studies have suggested a different role for this porin, finding a decrease in its expression in cases of antimicrobial resistance (31) , suggesting that this membrane protein could also be working as an entrance of the antibiotics into the bacteria.
Although more studies are necessary to determine non-identified resistance mechanisms, the low frequency of mutation together the low levels of resistance achieved in a single step highlight the low potential of selecting furazolidone-resistant mutants.
